SEC Form 4 · accession 0001712276-26-000009
RECURSION PHARMACEUTICALS, INC. · RXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ben R Taylor
Officer — Chief Financial Officer
Period of report
Aug 17, 2026
Accepted (ET)
Aug 18, 2026 · 5:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001601830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Aug 17, 2026 | F | 25,018 | $3.16 | D | 1,076,858 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.